Abnormal mixed leucocyte reaction in bone marrow aplasia
Related Articles
- Reversal of aplastic anaemia secondary to systemic lupus erythematosus by high-dose intravenous cyclophosphamide. Walport, M.J.; Hubbard, W.N.; Hughes, G.R.V. // British Medical Journal (Clinical Research Edition);9/18/1982, Vol. 285 Issue 6344, p769
Investigates the reversal of aplastic anemia secondary to systemic lupus erythematosus (SLE) by high-dose intravenous cyclophosphamide. Features of SLE; Presentation of a case report on patient with SLE with bone marrow aplasia; Reaction of patient to cyclophosphamide treatment.
- Use of lithium carbonate in the treatment of a suspected case of oestrogen-induced bone marrow aplasia in a bitch. de Oliveira Conrado, F.; de Ávila Rodrigues, B.; de Almeida Lacerda, L.; Lasta, C. Serina; Esteves, V. Sinnott; Gonzalez, F. H. Díaz // Veterinary Record: Journal of the British Veterinary Association;2/28/2009, Vol. 164 Issue 9, p274
A letter to the editor is presented discussing the application of lithium carbonate in treating a suspected case of bone marrow aplasia in a dog.
- Temozolomide. // Reactions Weekly;Jan2015, Vol. 1535 Issue 1, p197
The article focuses on the case studies about the development of anaemia, leucopenia and bone marrow aplasia following the administration of temozolomide.
- Reduced intensity conditioning bone marrow transplantation for pure red cell aplasia: successful outcome but difficult post transplant course. Kochethu, G.; Baden, H. S.; Jaworska, E.; Chang, J.; Chopra, R. // Bone Marrow Transplantation;Jul2005, Vol. 36 Issue 1, p81
Presents a letter to the editor discussing reduced intensity conditioning bone marrow transplantation for pure red cell aplasia.
- Recurrent bone marrow aplasia secondary to nilotinib in a patient with chronic myeloid leukemia: A case report. Prodduturi, Prathima; Perry, Anamarija M; Aoun, Patricia; Weisenburger, Dennis D; Akhtari, Mojtaba // Journal of Oncology Pharmacy Practice;Dec2012, Vol. 18 Issue 4, p440
Nilotinib is a potent tyrosine kinase inhibitor of breakpoint cluster region-abelson (BCR-ABL), which has been approved as front-line therapy for newly diagnosed chronic myeloid leukemia in chronic phase and as second-line therapy after imatinib failure in chronic or accelerated phase chronic...
- Pure red cell aplasia associated with Systemic Lupus Erythematosus. Koyama, R. V.; Silva, L. F.; Henriques, V. B.; Tran, C.; Yoshikawa, G. T. // Acta Reumatológica Portuguesa;jul-set2014, Vol. 39 Issue 3, p265
Pure red cell aplasia is a rare condition described in patients with autoimmune diseases such as systemic lupus erythematosus. Bone marrow examination of a 52-year-old female showed selective severe hypoplasia, scarce hematopoietic reserves, and no abnormality in other cell lineages, which are...
- Bone Marrow Transplantation and Leucocyte Transfusions (Book). // Annals of Internal Medicine;Dec71, Vol. 75 Issue 6, p979
Reviews the book 'Bone Marrow Transplantation and Leucocyte Transfusions,' by By Georges Math é, Jean-Louis Amiel, and Leon Schwarzenberg.
- pure white cell aplasia. // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1943
A definition of the term "pure white cell aplasia" which refers to bone marrow failure characterized by inability to manufacture and circulate leukocytes into the bloodstream is presented.
- Lenalidomide-Induced Pure Red Cell Aplasia. Dolai, Tuphan Kanti; Dutta, Shyamali; Mandal, Prakas Kumar; Saha, Sandeep; Bhattacharyya, Maitreyee // Turkish Journal of Hematology;Mar2014, Vol. 31 Issue 1, p99
A letter to the editor is presented related to the pure red cell aplasia, bone marrow failure disorder, induced by Lenalidomide, published in the March 2014 issue of the journal.
- Nilotinib. // Reactions Weekly;1/12/2013, Issue 1434, p48
The article describes the case of a 49-year-old man who experienced recurrent bone marrow aplasia while receiving nilotinib.
